Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCHâ„¢ developed by ... otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, who ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... unique opportunity for venture capital funds, investment firms and animal health companies to ... Forum have raised $160 million. Several have also received licensing agreements or distribution ...
(Date:8/27/2015)... Aug. 27, 2015  Neogen Corporation (NASDAQ: NEOG ... of United Kingdom -based Lab M ... media and diagnostic systems. Lab M ... leading provider of microbial testing and diagnostic products for ... The company currently sells into more than 70 countries ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" ... - BioMS Medical Corp (TSX: MS), a leading ... today announced that Mr. Richard Brown, Vice President, ... Senior Director, Corporate Business Development, Eli Lilly and ...
... May 14 - Bioniche Pharma, a leading ... launch of Enlon (R) (edrophonium chloride injection, ... sulfate, USP) Injection. (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO )"The ... Bioniche,s continued growth and a commitment to bringing ...
... 14 Nucletron, a,knowledge-based leader in radiation ... Brachy, a comprehensive film- and volume-based treatment,planning ... brachytherapy.,Oncentra Brachy, the world,s first fully DICOM-compatible ... system that features,state-of-the-art optimization algorithms to ensure ...
Cached Biology Technology:BioMS Medical to participate in panel session at Bio International Convention 2009 2Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... of Harvard and MIT today announced that they have ... from the National Institutes of Health (NIH) to identify ... can probe the proteins, signaling pathways and cellular processes ... Broad Institute is among nine institutions to receive funding ...
... America,s population, diabetes can lead to blindness, kidney failure, strokes ... new cure based on advances in cell therapy ... TAU,s Sackler Faculty of Medicine, whose research group is among ... to cultivate cells derived from insulin-producing beta cells from human ...
... Spanish . , Background , Many ... in childhood or adolescence. In fact some studies show that ... diagnostic criterion for a mental disorder before reaching adulthood. The ... serious in children than in adults in fact, childhood ...
Cached Biology News:Broad Institute awarded grant to develop chemical probes for human biology and disease 2Broad Institute awarded grant to develop chemical probes for human biology and disease 3Battling diabetes with beta cells 2Risks and benefits of antipsychotics in children and adolescents 2Risks and benefits of antipsychotics in children and adolescents 3Risks and benefits of antipsychotics in children and adolescents 4Risks and benefits of antipsychotics in children and adolescents 5
...
Anti Autotaxin /ENPP2 , - (Rabbit)...
...
... An N-nitroso-containing diabetogenic compound that acts ... pancreatic islets. An antibiotic effective against ... DNA strand breaks in pancreatic islet ... in H 2 O. RTECS LZ5775000, ...
Biology Products: